Mizuho Lowers Assembly Biosciences (NASDAQ:ASMB) Price Target to $45.00

Assembly Biosciences (NASDAQ:ASMB) had its price target dropped by equities research analysts at Mizuho from $53.00 to $45.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Mizuho’s price objective would suggest a potential upside of 34.69% from the company’s current price.

ASMB has been the topic of a number of other research reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Assembly Biosciences in a research report on Friday, July 17th. HC Wainwright reissued a “buy” rating and set a $50.00 price target on shares of Assembly Biosciences in a research report on Tuesday, August 18th. Guggenheim restated a “buy” rating and issued a $43.00 price target on shares of Assembly Biosciences in a research note on Thursday, May 28th. UBS Group started coverage on Assembly Biosciences in a research report on Tuesday. They set a “buy” rating and a $52.00 price target on the stock. Finally, Zacks Research upgraded Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.60.

Assembly Biosciences Stock Down 0.7%

ASMB traded down $0.22 during trading hours on Tuesday, hitting $33.41. 60,448 shares of the company’s stock were exchanged, compared to its average volume of 162,081. The stock has a market cap of $680.23 million, a price-to-earnings ratio of 33.01 and a beta of 1.10. Assembly Biosciences has a 1-year low of $20.23 and a 1-year high of $39.71. The stock’s 50-day moving average is $28.38 and its two-hundred day moving average is $27.94.

Assembly Biosciences (NASDAQ:ASMB) last issued its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.52. Assembly Biosciences had a negative net margin of 0.06% and a negative return on equity of 0.02%. The firm had revenue of $13.37 million for the quarter, compared to analyst estimates of $8.60 million. On average, equities research analysts anticipate that Assembly Biosciences will post 2.28 EPS for the current year.

Hedge Funds Weigh In On Assembly Biosciences

Several institutional investors and hedge funds have recently made changes to their positions in the company. Seven Fleet Capital Management LP increased its stake in shares of Assembly Biosciences by 671.5% during the second quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock worth $11,903,000 after purchasing an additional 377,000 shares during the period. Stempoint Capital LP grew its holdings in Assembly Biosciences by 18.3% in the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock valued at $5,146,000 after buying an additional 28,707 shares in the last quarter. Eversept Partners LP bought a new position in Assembly Biosciences during the 4th quarter worth $5,431,000. 683 Capital Management LLC bought a new position in Assembly Biosciences during the 4th quarter worth $948,000. Finally, Arrowstreet Capital Limited Partnership lifted its holdings in shares of Assembly Biosciences by 4.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 39,446 shares of the biopharmaceutical company’s stock worth $1,095,000 after buying an additional 1,634 shares in the last quarter. Institutional investors and hedge funds own 19.92% of the company’s stock.

About Assembly Biosciences

Assembly Biosciences, Inc (NASDAQ: ASMB) is a clinical-stage biotechnology company dedicated to the discovery, development and commercialization of novel therapies for hepatitis B virus (HBV) and hepatitis D virus (HDV) infections. The company’s core expertise lies in small-molecule modulation of viral proteins and host-targeted pathways to achieve sustained viral suppression and potential functional cure. Assembly’s research model integrates medicinal chemistry, structural biology and translational virology to advance its pipeline from early discovery through clinical development.

The company’s lead programs include core protein allosteric modulators (CpAMs) designed to disrupt the HBV lifecycle by interfering with capsid assembly and viral DNA replication, as well as prenylation inhibitors targeting the HDV lifecycle.